10-Q Filing
Filing Information
| Form Type | 10-Q |
| Accession Number | 0000950170-25-066940 |
| Period End Date | 20250331 |
| Filing Date | 20250508 |
| Fiscal Year | 2025 |
| Fiscal Period | Q1 |
| XBRL Instance | crgx-20250331_htm.xml |
Filing Contents
This filing contains the following financial statements:
Balance Sheet
104 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$61.77M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$61.77M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$81.53M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$81.53M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$64.38M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$64.38M | USD | Point-in-time |
| Short-term marketable securities |
MarketableSecuritiesCurrent
|
$275.32M | USD | Point-in-time |
| Short-term marketable securities |
MarketableSecuritiesCurrent
|
$275.32M | USD | Point-in-time |
| Short-term marketable securities |
MarketableSecuritiesCurrent
|
$257.07M | USD | Point-in-time |
| Short-term marketable securities |
MarketableSecuritiesCurrent
|
$257.07M | USD | Point-in-time |
| Assets held for sale |
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
|
$1.57M | USD | Point-in-time |
| Assets held for sale |
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
|
$1.57M | USD | Point-in-time |
| Prepaid expenses and other current assets |
PrepaidExpenseAndOtherAssetsCurrent
|
$5.31M | USD | Point-in-time |
| Prepaid expenses and other current assets |
PrepaidExpenseAndOtherAssetsCurrent
|
$5.31M | USD | Point-in-time |
| Prepaid expenses and other current assets |
PrepaidExpenseAndOtherAssetsCurrent
|
$4.40M | USD | Point-in-time |
| Prepaid expenses and other current assets |
PrepaidExpenseAndOtherAssetsCurrent
|
$4.40M | USD | Point-in-time |
| Total current assets |
AssetsCurrent
|
$324.81M | USD | Point-in-time |
| Total current assets |
AssetsCurrent
|
$324.81M | USD | Point-in-time |
| Total current assets |
AssetsCurrent
|
$345.01M | USD | Point-in-time |
| Total current assets |
AssetsCurrent
|
$345.01M | USD | Point-in-time |
| Long-term marketable securities |
MarketableSecuritiesNoncurrent
|
$28.39M | USD | Point-in-time |
| Long-term marketable securities |
MarketableSecuritiesNoncurrent
|
$28.39M | USD | Point-in-time |
| Long-term marketable securities |
MarketableSecuritiesNoncurrent
|
$12.44M | USD | Point-in-time |
| Long-term marketable securities |
MarketableSecuritiesNoncurrent
|
$12.44M | USD | Point-in-time |
| Operating lease right-of-use assets |
OperatingLeaseRightOfUseAsset
|
$23.48M | USD | Point-in-time |
| Operating lease right-of-use assets |
OperatingLeaseRightOfUseAsset
|
$23.48M | USD | Point-in-time |
| Operating lease right-of-use assets |
OperatingLeaseRightOfUseAsset
|
$22.93M | USD | Point-in-time |
| Operating lease right-of-use assets |
OperatingLeaseRightOfUseAsset
|
$22.93M | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Property and equipment, net |
PropertyPlantAndEquipmentNet
|
$11.29M | USD | Point-in-time |
| Property and equipment, net |
PropertyPlantAndEquipmentNet
|
$11.29M | USD | Point-in-time |
| Property and equipment, net |
PropertyPlantAndEquipmentNet
|
$1.11M | USD | Point-in-time |
| Property and equipment, net |
PropertyPlantAndEquipmentNet
|
$1.11M | USD | Point-in-time |
| Other non-current assets |
OtherAssetsNoncurrent
|
$93.00K | USD | Point-in-time |
| Other non-current assets |
OtherAssetsNoncurrent
|
$93.00K | USD | Point-in-time |
| Other non-current assets |
OtherAssetsNoncurrent
|
$5.31M | USD | Point-in-time |
| Other non-current assets |
OtherAssetsNoncurrent
|
$5.31M | USD | Point-in-time |
| Total assets |
Assets
|
$361.96M | USD | Point-in-time |
| Total assets |
Assets
|
$361.96M | USD | Point-in-time |
| Total assets |
Assets
|
$414.05M | USD | Point-in-time |
| Total assets |
Assets
|
$414.05M | USD | Point-in-time |
| Accounts payable |
AccountsPayableCurrent
|
$2.44M | USD | Point-in-time |
| Accounts payable |
AccountsPayableCurrent
|
$2.44M | USD | Point-in-time |
| Accounts payable |
AccountsPayableCurrent
|
$4.23M | USD | Point-in-time |
| Accounts payable |
AccountsPayableCurrent
|
$4.23M | USD | Point-in-time |
| Accrued clinical and research and development expenses |
AccruedClinicalAndResearchAndDevelopmentExpensesCurrent
|
$12.52M | USD | Point-in-time |
| Accrued clinical and research and development expenses |
AccruedClinicalAndResearchAndDevelopmentExpensesCurrent
|
$12.52M | USD | Point-in-time |
| Accrued clinical and research and development expenses |
AccruedClinicalAndResearchAndDevelopmentExpensesCurrent
|
$5.57M | USD | Point-in-time |
| Accrued clinical and research and development expenses |
AccruedClinicalAndResearchAndDevelopmentExpensesCurrent
|
$5.57M | USD | Point-in-time |
| Accrued expenses and other current liabilities |
AccruedExpensesAndOtherCurrentLiabilities
|
$2.34M | USD | Point-in-time |
| Accrued expenses and other current liabilities |
AccruedExpensesAndOtherCurrentLiabilities
|
$2.34M | USD | Point-in-time |
| Accrued expenses and other current liabilities |
AccruedExpensesAndOtherCurrentLiabilities
|
$9.44M | USD | Point-in-time |
| Accrued expenses and other current liabilities |
AccruedExpensesAndOtherCurrentLiabilities
|
$9.44M | USD | Point-in-time |
| Accrued restructuring costs |
AccruedRestructuringCosts
|
$36.92M | USD | Point-in-time |
| Accrued restructuring costs |
AccruedRestructuringCosts
|
$36.92M | USD | Point-in-time |
| Operating lease liabilities, current |
OperatingLeaseLiabilityCurrent
|
$628.00K | USD | Point-in-time |
| Operating lease liabilities, current |
OperatingLeaseLiabilityCurrent
|
$628.00K | USD | Point-in-time |
| Operating lease liabilities, current |
OperatingLeaseLiabilityCurrent
|
$2.50M | USD | Point-in-time |
| Operating lease liabilities, current |
OperatingLeaseLiabilityCurrent
|
$2.50M | USD | Point-in-time |
| Total current liabilities |
LiabilitiesCurrent
|
$25.03M | USD | Point-in-time |
| Total current liabilities |
LiabilitiesCurrent
|
$25.03M | USD | Point-in-time |
| Total current liabilities |
LiabilitiesCurrent
|
$51.55M | USD | Point-in-time |
| Total current liabilities |
LiabilitiesCurrent
|
$51.55M | USD | Point-in-time |
| Operating lease liabilities, non-current |
OperatingLeaseLiabilityNoncurrent
|
$28.80M | USD | Point-in-time |
| Operating lease liabilities, non-current |
OperatingLeaseLiabilityNoncurrent
|
$28.80M | USD | Point-in-time |
| Operating lease liabilities, non-current |
OperatingLeaseLiabilityNoncurrent
|
$27.95M | USD | Point-in-time |
| Operating lease liabilities, non-current |
OperatingLeaseLiabilityNoncurrent
|
$27.95M | USD | Point-in-time |
| Total liabilities |
Liabilities
|
$79.50M | USD | Point-in-time |
| Total liabilities |
Liabilities
|
$79.50M | USD | Point-in-time |
| Total liabilities |
Liabilities
|
$53.83M | USD | Point-in-time |
| Total liabilities |
Liabilities
|
$53.83M | USD | Point-in-time |
| Common stock |
CommonStockValue
|
$46.00K | USD | Point-in-time |
| Common stock |
CommonStockValue
|
$46.00K | USD | Point-in-time |
| Common stock |
CommonStockValue
|
$46.00K | USD | Point-in-time |
| Common stock |
CommonStockValue
|
$46.00K | USD | Point-in-time |
| Additional paid-in capital |
AdditionalPaidInCapital
|
$672.54M | USD | Point-in-time |
| Additional paid-in capital |
AdditionalPaidInCapital
|
$672.54M | USD | Point-in-time |
| Additional paid-in capital |
AdditionalPaidInCapital
|
$679.46M | USD | Point-in-time |
| Additional paid-in capital |
AdditionalPaidInCapital
|
$679.46M | USD | Point-in-time |
| Accumulated other comprehensive income |
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
$291.00K | USD | Point-in-time |
| Accumulated other comprehensive income |
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
$291.00K | USD | Point-in-time |
| Accumulated other comprehensive income |
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
$96.00K | USD | Point-in-time |
| Accumulated other comprehensive income |
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
$96.00K | USD | Point-in-time |
| Accumulated deficit |
RetainedEarningsAccumulatedDeficit
|
$-312.65M | USD | Point-in-time |
| Accumulated deficit |
RetainedEarningsAccumulatedDeficit
|
$-312.65M | USD | Point-in-time |
| Accumulated deficit |
RetainedEarningsAccumulatedDeficit
|
$-397.15M | USD | Point-in-time |
| Accumulated deficit |
RetainedEarningsAccumulatedDeficit
|
$-397.15M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$373.21M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$373.21M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$360.23M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$360.23M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$282.46M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$282.46M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$405.39M | USD | Point-in-time |
| Total stockholders' equity |
StockholdersEquity
|
$405.39M | USD | Point-in-time |
| Total liabilities and stockholders' equity |
LiabilitiesAndStockholdersEquity
|
$414.05M | USD | Point-in-time |
| Total liabilities and stockholders' equity |
LiabilitiesAndStockholdersEquity
|
$414.05M | USD | Point-in-time |
| Total liabilities and stockholders' equity |
LiabilitiesAndStockholdersEquity
|
$361.96M | USD | Point-in-time |
| Total liabilities and stockholders' equity |
LiabilitiesAndStockholdersEquity
|
$361.96M | USD | Point-in-time |
Income Statement
54 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Research and development |
ResearchAndDevelopmentExpense
|
$30.64M | USD | 1 Quarter |
| Research and development |
ResearchAndDevelopmentExpense
|
$30.64M | USD | 1 Quarter |
| Research and development |
ResearchAndDevelopmentExpense
|
$30.50M | USD | 1 Quarter |
| Research and development |
ResearchAndDevelopmentExpense
|
$30.50M | USD | 1 Quarter |
| General and administrative |
GeneralAndAdministrativeExpense
|
$10.30M | USD | 1 Quarter |
| General and administrative |
GeneralAndAdministrativeExpense
|
$10.30M | USD | 1 Quarter |
| General and administrative |
GeneralAndAdministrativeExpense
|
$11.51M | USD | 1 Quarter |
| General and administrative |
GeneralAndAdministrativeExpense
|
$11.51M | USD | 1 Quarter |
| Restructuring, impairment, and costs of suspended programs |
RestructuringCostsAndAssetImpairmentCharges
|
$46.28M | USD | 1 Quarter |
| Restructuring, impairment, and costs of suspended programs |
RestructuringCostsAndAssetImpairmentCharges
|
$46.28M | USD | 1 Quarter |
| Total operating expenses |
OperatingExpenses
|
$88.42M | USD | 1 Quarter |
| Total operating expenses |
OperatingExpenses
|
$88.42M | USD | 1 Quarter |
| Total operating expenses |
OperatingExpenses
|
$40.81M | USD | 1 Quarter |
| Total operating expenses |
OperatingExpenses
|
$40.81M | USD | 1 Quarter |
| Loss from operations |
OperatingIncomeLoss
|
$-88.42M | USD | 1 Quarter |
| Loss from operations |
OperatingIncomeLoss
|
$-88.42M | USD | 1 Quarter |
| Loss from operations |
OperatingIncomeLoss
|
$-40.81M | USD | 1 Quarter |
| Loss from operations |
OperatingIncomeLoss
|
$-40.81M | USD | 1 Quarter |
| Interest income |
InvestmentIncomeInterest
|
$5.00M | USD | 1 Quarter |
| Interest income |
InvestmentIncomeInterest
|
$5.00M | USD | 1 Quarter |
| Interest income |
InvestmentIncomeInterest
|
$3.94M | USD | 1 Quarter |
| Interest income |
InvestmentIncomeInterest
|
$3.94M | USD | 1 Quarter |
| Other expense, net |
OtherNonoperatingIncomeExpense
|
$-10.00K | USD | 1 Quarter |
| Other expense, net |
OtherNonoperatingIncomeExpense
|
$-10.00K | USD | 1 Quarter |
| Other expense, net |
OtherNonoperatingIncomeExpense
|
$-11.00K | USD | 1 Quarter |
| Other expense, net |
OtherNonoperatingIncomeExpense
|
$-11.00K | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-35.81M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-35.81M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-84.50M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-84.50M | USD | 1 Quarter |
| Unrealized loss on marketable securities |
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
$-279.00K | USD | 1 Quarter |
| Unrealized loss on marketable securities |
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
$-279.00K | USD | 1 Quarter |
| Unrealized loss on marketable securities |
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
$-195.00K | USD | 1 Quarter |
| Unrealized loss on marketable securities |
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
$-195.00K | USD | 1 Quarter |
| Comprehensive loss |
ComprehensiveIncomeNetOfTax
|
$-36.09M | USD | 1 Quarter |
| Comprehensive loss |
ComprehensiveIncomeNetOfTax
|
$-36.09M | USD | 1 Quarter |
| Comprehensive loss |
ComprehensiveIncomeNetOfTax
|
$-84.69M | USD | 1 Quarter |
| Comprehensive loss |
ComprehensiveIncomeNetOfTax
|
$-84.69M | USD | 1 Quarter |
| Net loss per share attributable to common stockholders, basic |
EarningsPerShareBasic
|
$-1.77 | USD | 1 Quarter |
| Net loss per share attributable to common stockholders, basic |
EarningsPerShareBasic
|
$-1.77 | USD | 1 Quarter |
| Net loss per share attributable to common stockholders, basic |
EarningsPerShareBasic
|
$-0.87 | USD | 1 Quarter |
| Net loss per share attributable to common stockholders, basic |
EarningsPerShareBasic
|
$-0.87 | USD | 1 Quarter |
| Net loss per share attributable to common stockholders, diluted |
EarningsPerShareDiluted
|
$-0.87 | USD | 1 Quarter |
| Net loss per share attributable to common stockholders, diluted |
EarningsPerShareDiluted
|
$-0.87 | USD | 1 Quarter |
| Net loss per share attributable to common stockholders, diluted |
EarningsPerShareDiluted
|
$-1.77 | USD | 1 Quarter |
| Net loss per share attributable to common stockholders, diluted |
EarningsPerShareDiluted
|
$-1.77 | USD | 1 Quarter |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic |
WeightedAverageNumberOfSharesOutstandingBasic
|
41.00M | shares | 1 Quarter |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic |
WeightedAverageNumberOfSharesOutstandingBasic
|
41.00M | shares | 1 Quarter |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic |
WeightedAverageNumberOfSharesOutstandingBasic
|
47.85M | shares | 1 Quarter |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic |
WeightedAverageNumberOfSharesOutstandingBasic
|
47.85M | shares | 1 Quarter |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted |
WeightedAverageNumberOfDilutedSharesOutstanding
|
41.00M | shares | 1 Quarter |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted |
WeightedAverageNumberOfDilutedSharesOutstanding
|
41.00M | shares | 1 Quarter |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted |
WeightedAverageNumberOfDilutedSharesOutstanding
|
47.85M | shares | 1 Quarter |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted |
WeightedAverageNumberOfDilutedSharesOutstanding
|
47.85M | shares | 1 Quarter |
Cash Flow Statement
136 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Net loss |
NetIncomeLoss
|
$-35.81M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-35.81M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-84.50M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-84.50M | USD | 1 Quarter |
| Stock-based compensation expense |
ShareBasedCompensation
|
$6.88M | USD | 1 Quarter |
| Stock-based compensation expense |
ShareBasedCompensation
|
$6.88M | USD | 1 Quarter |
| Stock-based compensation expense |
ShareBasedCompensation
|
$3.90M | USD | 1 Quarter |
| Stock-based compensation expense |
ShareBasedCompensation
|
$3.90M | USD | 1 Quarter |
| Amortization of operating lease right-of-use assets |
OperatingLeaseRightOfUseAssetAmortizationExpense
|
$548.00K | USD | 1 Quarter |
| Amortization of operating lease right-of-use assets |
OperatingLeaseRightOfUseAssetAmortizationExpense
|
$548.00K | USD | 1 Quarter |
| Amortization of operating lease right-of-use assets |
OperatingLeaseRightOfUseAssetAmortizationExpense
|
$1.30M | USD | 1 Quarter |
| Amortization of operating lease right-of-use assets |
OperatingLeaseRightOfUseAssetAmortizationExpense
|
$1.30M | USD | 1 Quarter |
| Depreciation |
Depreciation
|
$553.00K | USD | 1 Quarter |
| Depreciation |
Depreciation
|
$553.00K | USD | 1 Quarter |
| Depreciation |
Depreciation
|
$672.00K | USD | 1 Quarter |
| Depreciation |
Depreciation
|
$672.00K | USD | 1 Quarter |
| Impairment of property and equipment |
ImpairmentOfLongLivedAssetsHeldForUse
|
$8.03M | USD | 1 Quarter |
| Impairment of property and equipment |
ImpairmentOfLongLivedAssetsHeldForUse
|
$8.03M | USD | 1 Quarter |
| Acquired in-process research and development |
AcquiredInProcessResearchAndDevelopment
|
$150.00K | USD | 1 Quarter |
| Acquired in-process research and development |
AcquiredInProcessResearchAndDevelopment
|
$150.00K | USD | 1 Quarter |
| Acquired in-process research and development |
AcquiredInProcessResearchAndDevelopment
|
$665.00K | USD | 1 Quarter |
| Acquired in-process research and development |
AcquiredInProcessResearchAndDevelopment
|
$665.00K | USD | 1 Quarter |
| Accretion on investments in marketable securities |
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
$2.33M | USD | 1 Quarter |
| Accretion on investments in marketable securities |
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
$2.33M | USD | 1 Quarter |
| Accretion on investments in marketable securities |
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
$1.60M | USD | 1 Quarter |
| Accretion on investments in marketable securities |
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
$1.60M | USD | 1 Quarter |
| Prepaid expenses and other current assets |
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
$-904.00K | USD | 1 Quarter |
| Prepaid expenses and other current assets |
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
$-904.00K | USD | 1 Quarter |
| Prepaid expenses and other current assets |
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
$391.00K | USD | 1 Quarter |
| Prepaid expenses and other current assets |
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
$391.00K | USD | 1 Quarter |
| Other non-current assets |
IncreaseDecreaseInOtherNoncurrentAssets
|
$-5.22M | USD | 1 Quarter |
| Other non-current assets |
IncreaseDecreaseInOtherNoncurrentAssets
|
$-5.22M | USD | 1 Quarter |
| Other non-current assets |
IncreaseDecreaseInOtherNoncurrentAssets
|
$-10.00K | USD | 1 Quarter |
| Other non-current assets |
IncreaseDecreaseInOtherNoncurrentAssets
|
$-10.00K | USD | 1 Quarter |
| Accounts payable |
IncreaseDecreaseInAccountsPayable
|
$1.60M | USD | 1 Quarter |
| Accounts payable |
IncreaseDecreaseInAccountsPayable
|
$1.60M | USD | 1 Quarter |
| Accounts payable |
IncreaseDecreaseInAccountsPayable
|
$2.67M | USD | 1 Quarter |
| Accounts payable |
IncreaseDecreaseInAccountsPayable
|
$2.67M | USD | 1 Quarter |
| Accrued clinical and research and development expenses |
IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses
|
$-6.94M | USD | 1 Quarter |
| Accrued clinical and research and development expenses |
IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses
|
$-6.94M | USD | 1 Quarter |
| Accrued clinical and research and development expenses |
IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses
|
$3.27M | USD | 1 Quarter |
| Accrued clinical and research and development expenses |
IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses
|
$3.27M | USD | 1 Quarter |
| Accrued expenses and other current liabilities |
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
|
$-3.15M | USD | 1 Quarter |
| Accrued expenses and other current liabilities |
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
|
$-3.15M | USD | 1 Quarter |
| Accrued expenses and other current liabilities |
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
|
$-7.11M | USD | 1 Quarter |
| Accrued expenses and other current liabilities |
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
|
$-7.11M | USD | 1 Quarter |
| Accrued restructuring costs |
IncreaseDecreaseInAccruedRestructuringCosts
|
$36.92M | USD | 1 Quarter |
| Accrued restructuring costs |
IncreaseDecreaseInAccruedRestructuringCosts
|
$36.92M | USD | 1 Quarter |
| Operating lease liabilities |
IncreaseDecreaseInOperatingLeaseLiability
|
$1.02M | USD | 1 Quarter |
| Operating lease liabilities |
IncreaseDecreaseInOperatingLeaseLiability
|
$1.02M | USD | 1 Quarter |
| Operating lease liabilities |
IncreaseDecreaseInOperatingLeaseLiability
|
$-336.00K | USD | 1 Quarter |
| Operating lease liabilities |
IncreaseDecreaseInOperatingLeaseLiability
|
$-336.00K | USD | 1 Quarter |
| Net cash used in operating activities |
NetCashProvidedByUsedInOperatingActivities
|
$-37.69M | USD | 1 Quarter |
| Net cash used in operating activities |
NetCashProvidedByUsedInOperatingActivities
|
$-37.69M | USD | 1 Quarter |
| Net cash used in operating activities |
NetCashProvidedByUsedInOperatingActivities
|
$-30.15M | USD | 1 Quarter |
| Net cash used in operating activities |
NetCashProvidedByUsedInOperatingActivities
|
$-30.15M | USD | 1 Quarter |
| Purchases of marketable securities |
PaymentsToAcquireMarketableSecurities
|
$292.34M | USD | 1 Quarter |
| Purchases of marketable securities |
PaymentsToAcquireMarketableSecurities
|
$292.34M | USD | 1 Quarter |
| Purchases of marketable securities |
PaymentsToAcquireMarketableSecurities
|
$81.69M | USD | 1 Quarter |
| Purchases of marketable securities |
PaymentsToAcquireMarketableSecurities
|
$81.69M | USD | 1 Quarter |
| Proceeds from sales and maturities of marketable securities |
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
$117.29M | USD | 1 Quarter |
| Proceeds from sales and maturities of marketable securities |
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
$117.29M | USD | 1 Quarter |
| Purchase of property and equipment |
PaymentsToAcquirePropertyPlantAndEquipment
|
$1.29M | USD | 1 Quarter |
| Purchase of property and equipment |
PaymentsToAcquirePropertyPlantAndEquipment
|
$1.29M | USD | 1 Quarter |
| Purchase of property and equipment |
PaymentsToAcquirePropertyPlantAndEquipment
|
$382.00K | USD | 1 Quarter |
| Purchase of property and equipment |
PaymentsToAcquirePropertyPlantAndEquipment
|
$382.00K | USD | 1 Quarter |
| Purchase of in-process research and development |
PaymentsToAcquireInProcessResearchAndDevelopment
|
$330.00K | USD | 1 Quarter |
| Purchase of in-process research and development |
PaymentsToAcquireInProcessResearchAndDevelopment
|
$330.00K | USD | 1 Quarter |
| Purchase of in-process research and development |
PaymentsToAcquireInProcessResearchAndDevelopment
|
$183.00K | USD | 1 Quarter |
| Purchase of in-process research and development |
PaymentsToAcquireInProcessResearchAndDevelopment
|
$183.00K | USD | 1 Quarter |
| Net cash provided by (used in) investing activities |
NetCashProvidedByUsedInInvestingActivities
|
$35.04M | USD | 1 Quarter |
| Net cash provided by (used in) investing activities |
NetCashProvidedByUsedInInvestingActivities
|
$35.04M | USD | 1 Quarter |
| Net cash provided by (used in) investing activities |
NetCashProvidedByUsedInInvestingActivities
|
$-293.96M | USD | 1 Quarter |
| Net cash provided by (used in) investing activities |
NetCashProvidedByUsedInInvestingActivities
|
$-293.96M | USD | 1 Quarter |
| Proceeds from exercise of stock options |
ProceedsFromStockOptionsExercised
|
$38.00K | USD | 1 Quarter |
| Proceeds from exercise of stock options |
ProceedsFromStockOptionsExercised
|
$38.00K | USD | 1 Quarter |
| Proceeds from exercise of stock options |
ProceedsFromStockOptionsExercised
|
$26.00K | USD | 1 Quarter |
| Proceeds from exercise of stock options |
ProceedsFromStockOptionsExercised
|
$26.00K | USD | 1 Quarter |
| Payment of deferred initial public offering costs |
PaymentsOfStockIssuanceCosts
|
$105.00K | USD | 1 Quarter |
| Payment of deferred initial public offering costs |
PaymentsOfStockIssuanceCosts
|
$105.00K | USD | 1 Quarter |
| Payment of transaction costs for exchange of common stock for warrants |
PaymentOfTransactionCostsForExchangeOfCommonStockForWarrants
|
$25.00K | USD | 1 Quarter |
| Payment of transaction costs for exchange of common stock for warrants |
PaymentOfTransactionCostsForExchangeOfCommonStockForWarrants
|
$25.00K | USD | 1 Quarter |
| Net cash provided by (used in) financing activities |
NetCashProvidedByUsedInFinancingActivities
|
$38.00K | USD | 1 Quarter |
| Net cash provided by (used in) financing activities |
NetCashProvidedByUsedInFinancingActivities
|
$38.00K | USD | 1 Quarter |
| Net cash provided by (used in) financing activities |
NetCashProvidedByUsedInFinancingActivities
|
$-104.00K | USD | 1 Quarter |
| Net cash provided by (used in) financing activities |
NetCashProvidedByUsedInFinancingActivities
|
$-104.00K | USD | 1 Quarter |
| Net decrease in cash, cash equivalents and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
$-324.21M | USD | 1 Quarter |
| Net decrease in cash, cash equivalents and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
$-324.21M | USD | 1 Quarter |
| Net decrease in cash, cash equivalents and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
$-2.61M | USD | 1 Quarter |
| Net decrease in cash, cash equivalents and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
$-2.61M | USD | 1 Quarter |
| Cash, cash equivalents, and restricted cash at beginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$64.95M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at beginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$64.95M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at beginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$62.33M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at beginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$62.33M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at beginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$82.09M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at beginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$82.09M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at beginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$406.30M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at beginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$406.30M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at end of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$64.95M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at end of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$64.95M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at end of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$62.33M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at end of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$62.33M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at end of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$82.09M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at end of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$82.09M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at end of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$406.30M | USD | Point-in-time |
| Cash, cash equivalents, and restricted cash at end of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$406.30M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$61.77M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$61.77M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$81.53M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$81.53M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$64.38M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$64.38M | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Restricted cash |
RestrictedCashNoncurrent
|
$567.00K | USD | Point-in-time |
| Total cash, cash equivalents, and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$64.95M | USD | Point-in-time |
| Total cash, cash equivalents, and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$64.95M | USD | Point-in-time |
| Total cash, cash equivalents, and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$62.33M | USD | Point-in-time |
| Total cash, cash equivalents, and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$62.33M | USD | Point-in-time |
| Total cash, cash equivalents, and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$82.09M | USD | Point-in-time |
| Total cash, cash equivalents, and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$82.09M | USD | Point-in-time |
| Total cash, cash equivalents, and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$406.30M | USD | Point-in-time |
| Total cash, cash equivalents, and restricted cash |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
$406.30M | USD | Point-in-time |
| Exchange of common stock for pre-funded warrants |
ExchangeOfCommonStockForPrefundedWarrants
|
$37.60M | USD | 1 Quarter |
| Exchange of common stock for pre-funded warrants |
ExchangeOfCommonStockForPrefundedWarrants
|
$37.60M | USD | 1 Quarter |
| Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities |
CapitalExpendituresIncurredButNotYetPaid
|
$100.00K | USD | 1 Quarter |
| Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities |
CapitalExpendituresIncurredButNotYetPaid
|
$100.00K | USD | 1 Quarter |
| Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities |
CapitalExpendituresIncurredButNotYetPaid
|
$379.00K | USD | 1 Quarter |
| Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities |
CapitalExpendituresIncurredButNotYetPaid
|
$379.00K | USD | 1 Quarter |
| In-process research and development costs in accounts payable and accrued clinical and research and development expenses |
InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedClinicalAndResearchAndDevelopmentExpenses
|
$993.00K | USD | 1 Quarter |
| In-process research and development costs in accounts payable and accrued clinical and research and development expenses |
InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedClinicalAndResearchAndDevelopmentExpenses
|
$993.00K | USD | 1 Quarter |
| In-process research and development costs in accounts payable and accrued clinical and research and development expenses |
InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedClinicalAndResearchAndDevelopmentExpenses
|
$1.00M | USD | 1 Quarter |
| In-process research and development costs in accounts payable and accrued clinical and research and development expenses |
InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedClinicalAndResearchAndDevelopmentExpenses
|
$1.00M | USD | 1 Quarter |
Stockholders Equity
40 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Beginning balance, amount |
StockholdersEquity
|
$373.21M | USD | Point-in-time |
| Beginning balance, amount |
StockholdersEquity
|
$373.21M | USD | Point-in-time |
| Beginning balance, amount |
StockholdersEquity
|
$360.23M | USD | Point-in-time |
| Beginning balance, amount |
StockholdersEquity
|
$360.23M | USD | Point-in-time |
| Beginning balance, amount |
StockholdersEquity
|
$282.46M | USD | Point-in-time |
| Beginning balance, amount |
StockholdersEquity
|
$282.46M | USD | Point-in-time |
| Beginning balance, amount |
StockholdersEquity
|
$405.39M | USD | Point-in-time |
| Beginning balance, amount |
StockholdersEquity
|
$405.39M | USD | Point-in-time |
| Exchange of common stock for pre-funded warrants, value |
ExchangeOfCommonStockForPrefundedWarrantsValue
|
$25.00K | USD | 1 Quarter |
| Exchange of common stock for pre-funded warrants, value |
ExchangeOfCommonStockForPrefundedWarrantsValue
|
$25.00K | USD | 1 Quarter |
| Exercise of stock options, shares |
StockIssuedDuringPeriodSharesStockOptionsExercised
|
12,447.00 | shares | 1 Quarter |
| Exercise of stock options, shares |
StockIssuedDuringPeriodSharesStockOptionsExercised
|
12,447.00 | shares | 1 Quarter |
| Exercise of stock options, amount |
StockIssuedDuringPeriodValueStockOptionsExercised
|
$38.00K | USD | 1 Quarter |
| Exercise of stock options, amount |
StockIssuedDuringPeriodValueStockOptionsExercised
|
$38.00K | USD | 1 Quarter |
| Exercise of stock options, amount |
StockIssuedDuringPeriodValueStockOptionsExercised
|
$26.00K | USD | 1 Quarter |
| Exercise of stock options, amount |
StockIssuedDuringPeriodValueStockOptionsExercised
|
$26.00K | USD | 1 Quarter |
| Vesting of restricted stock |
VestingOfRestrictedStockAwardValue
|
$11.00K | USD | 1 Quarter |
| Vesting of restricted stock |
VestingOfRestrictedStockAwardValue
|
$11.00K | USD | 1 Quarter |
| Vesting of restricted stock |
VestingOfRestrictedStockAwardValue
|
$7.00K | USD | 1 Quarter |
| Vesting of restricted stock |
VestingOfRestrictedStockAwardValue
|
$7.00K | USD | 1 Quarter |
| Stock-based compensation |
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
$6.88M | USD | 1 Quarter |
| Stock-based compensation |
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
$6.88M | USD | 1 Quarter |
| Stock-based compensation |
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
$3.90M | USD | 1 Quarter |
| Stock-based compensation |
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
$3.90M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-35.81M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-35.81M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-84.50M | USD | 1 Quarter |
| Net loss |
NetIncomeLoss
|
$-84.50M | USD | 1 Quarter |
| Other comprehensive loss |
OtherComprehensiveIncomeLossNetOfTax
|
$-195.00K | USD | 1 Quarter |
| Other comprehensive loss |
OtherComprehensiveIncomeLossNetOfTax
|
$-195.00K | USD | 1 Quarter |
| Other comprehensive loss |
OtherComprehensiveIncomeLossNetOfTax
|
$-279.00K | USD | 1 Quarter |
| Other comprehensive loss |
OtherComprehensiveIncomeLossNetOfTax
|
$-279.00K | USD | 1 Quarter |
| Ending balance, amount |
StockholdersEquity
|
$373.21M | USD | Point-in-time |
| Ending balance, amount |
StockholdersEquity
|
$373.21M | USD | Point-in-time |
| Ending balance, amount |
StockholdersEquity
|
$360.23M | USD | Point-in-time |
| Ending balance, amount |
StockholdersEquity
|
$360.23M | USD | Point-in-time |
| Ending balance, amount |
StockholdersEquity
|
$282.46M | USD | Point-in-time |
| Ending balance, amount |
StockholdersEquity
|
$282.46M | USD | Point-in-time |
| Ending balance, amount |
StockholdersEquity
|
$405.39M | USD | Point-in-time |
| Ending balance, amount |
StockholdersEquity
|
$405.39M | USD | Point-in-time |
Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.